Dex Pharma Glow 70mg

BPC-157 + TB-500 + GHK-Cu Research Combination

Dex Pharma Glow is a three-peptide research formulation combining BPC-157, TB-500 and GHK-Cu in a single 70mg vial.

The formulation contains:

• 10mg BPC-157

• 10mg TB-500

• 50mg GHK-Cu

Together, these three peptides represent distinct areas of peptide and molecular biology research, including studies involving cellular signalling, extracellular-matrix biology, tissue remodelling and related biological pathways.

Research Overview

BPC-157

BPC-157 is a synthetic pentadecapeptide that has been investigated extensively in preclinical research, particularly in models involving gastrointestinal, vascular and musculoskeletal biology.

Published literature has reported promising findings in animal models, although translation to human clinical applications remains unconfirmed.

TB-500

TB-500 is commonly associated with research surrounding thymosin beta-4-related biology, including cellular migration, cytoskeletal processes and tissue-repair pathways.

Research reviews describe mechanisms involving cell migration, actin-related processes and signalling pathways, while also emphasizing the limited human clinical evidence available for these compounds.

GHK-Cu

GHK-Cu, also known as copper tripeptide or glycyl-L-histidyl-L-lysine copper, is a naturally occurring copper-binding peptide that has been investigated in relation to extracellular-matrix biology, collagen-related processes, cellular signalling and tissue-remodelling research.

Why These Three Peptides Are Studied Together

BPC-157, TB-500 and GHK-Cu have different research profiles and mechanisms.

Current literature describes areas including:

• Cellular signalling

• Angiogenesis research

• Cell migration

• Extracellular-matrix remodelling

• Fibroblast activity

• Collagen-related pathways

• Inflammation-related signalling

• Peptide-receptor interactions

Importantly, research into the individual compounds should not be interpreted as evidence that the combined formulation produces a clinically established effect. Current reviews highlight the limited human evidence surrounding several emerging peptide compounds.

Product Specifications

Product: Dex Pharma Glow
Total peptide content: 70mg per vial
BPC-157: 10mg
TB-500: 10mg
GHK-Cu: 50mg
Format: Lyophilised peptide formulation
Research category: Peptide research
Vial: 1 × 70mg total peptide formulation

Research Reference & Study Protocol Notes

Dex Pharma Glow is presented for research and educational reference purposes.

Health-Tech does not provide human-use dosing, administration instructions, treatment protocols or medical recommendations for this product.

Researchers should determine appropriate experimental concentrations, preparation methods, handling procedures and study conditions according to their own validated laboratory protocols, institutional requirements and applicable regulations.

Important Research & Regulatory Information

BPC-157 and TB-500 are among the peptide products specifically identified in SAHPRA's current public information concerning unregistered peptide products. SAHPRA states that products intended to treat, prevent or alter bodily functions require registration before being sold for those purposes in South Africa.

Research findings surrounding BPC-157, TB-500 and GHK-Cu remain an evolving area of scientific investigation. Recent reviews note that much of the evidence for emerging peptide compounds remains preclinical and that robust human safety and efficacy data are limited.

For research use only. Not intended for human consumption or self-administration.